National Vision price to free cash flow EYE

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 30.1×
8-year median: 31.5×
Against its 8-year history: 46th; percentile: 0 is its lowest day, 100 its highest
8-year range: 11.7× to 494×
Peer median: 21.9×

National Vision's price to free cash flow is 30.1× as of Oct 23, 2026.

That is below its 8-year median of 31.5×, close to the middle of its last 8 years.

Over that time it ranged from 11.7× in Jun 2026 to 494× in Dec 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 21.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	30.1×	11.7×	31.1×
2025	26.8×	22.7×	42.9×
2024	31.0×	21.1×	78.0×
2023	39.2×	34.5×	313×
2022	129×	17.7×	136×
2021	23.3×	16.8×	31.5×
2020	27.8×	17.7×	82.2×
2019	44.0×	36.7×	492×
2018	442×	403×	494×

Against its peers

Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first, today.

Company	Price to free cash flow
EYENational Vision	30.1×
CDRECadre	16.4×
BVSBioventus	13.3×
STAAStaar Surgical	n/m
LMATLemaitre Vascular	26.2×
IRMDIradimed	43.7×
INSPInspire Medical Systems	17.6×
UFPTUFP Technologies	n/m
ATRCAtriCure	56.5×
MOVMovado	9.8×
WRBYWarby Parker	147×
Peer median	21.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on National Vision

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.